Parvovirus infection В19V: literature review. Part 1

V.T. Kiriienko, I.A. Zaytsev, V.V. Potii, Ye.S. Nesteruk


The modern data about different aspects of the problem of parvovirus infection are presented in the article. Based on the analysis of literature data, the etiology, epidemio­logy, routes of infection, features of pathogenesis in an adult and fetal parvovirus infection are described. Clinical manifestations of the main forms of disease are presented.


parvovirus infection; etiology; epidemiology; cli­nical manifestations


Neu N. et al. TORCH Infections. Clin. Perinatol. 2015. 42. 77. Available from: [], last accessed Sept 13, 2018.

Cossart Y.E., Field A.M., Cаnt B., Widdows D. Parvovius-like particles in human sera. Lancet. 1975. 1 (7898). 72-73.

Zadori Z., Szelei J., Lacoste M.C. et al. A viral phospholipase A2 is required for parvovirus infectivity. Dev. Cell. 2001. 1. 291-302.

Kaufmann B., Chipman P.R., Kostyuchenko V.A. et al. Visualization of the externalized VP2 N termini of infectious human parvovirus B19. J. Virol. 2008. 82. 7306-7312.

Wan Z., Zhi N., Wong S. et al. Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2 F family of transcription factors. J. Clin. Invest. 2010. 120. 3530-3544.

Servant-Delmas A., Lefrère J.J., Morinet F., Pillet S. Advances in human B19 erythrovirus biology. J. Virol. 2010. 84 (19). 9658-65.

Chen A.Y. et al. The small 11 kDa non-structural protein of human parvovirus B19 plays a key role in inducing apoptosis du­ring B19 virus infection of primary erythroid progenitor cells. Blood. 2010. 115. 1070-1080.

Brown K.E., Hibbs J.R., Gallinella G. et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen). NEJM. 1994. 330. 1192-1196.

Kaufmann B. et al. The structure of human parvovirus B19. Proc. Natl. Acad. Sci. USA. 2004. 101. 11628-11633.

Schneider B., Höne A., Tolba R.H., Fischer Y.-P., Blümel J., Eis-Hübinger A.M. Simultaneous persistence of multiple genome variants of human parvovirus B19. J. Gen. Virol. 2008. 89. 164-176.

Servant A., Laperche S., Lallemand F. et al. Genetic diversity within human erythroviruses: identification of three genotypes. J. Virol. 2002. 76. 9124.

Parsyan A., Szmaragd C., Allain J.P., Candotti D. Identification and genetic diversity of two human parvovirus B19 genotype 3 subtypes. J. Gen. Virol. 2007. 88. 428.

Stelma F.F. et al. Occupational risk of human cytomegalovirus and parvovirus B19 infection in female day care personnel in the Netherlands; a study based on seroprevalence. Eur. J. Clin. Microbiol. Infect. Dis. 2009. 28. 393-397.

Anderson L.J. et al. Risk of infection following exposures to human parvovirus B19. Behring Inst. Mitt. 1990. 85. 60-63.

Jordan J., Tiangco B., Kiss J., Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998. 75. 97-102.

Lamont R.F., Sobel J., Vaisbuch E. et al. Parvovirus B19 infection in human pregnancy. BJOG. 2011. 118 (2). 175-186.

Климович Н.В., Матвеев В.Л., Романов О.М., Черновецкий М.А. Эпидемиологическая характеристика парвовирусной инфекции у детей с гематологическими заболеваниями. Охрана материнства и детства. 2011. 1. 42-46.

Kleinman S.H., Glynn S.A., Lee T.H., Tobler L., Montalvo L., Todd D., Kiss J.E., Shyamala V., Busch M.P. Prevalence and quantitation of parvovirus B19 DNA levels in blood donors with a sensitive polymerase chain reaction screening assay. Transfusion. 2007. 47 (10). 1756.

Kleinman S.H., Glynn S.A., Lee T.H., Tobler L.H., Schlumpf K.S., Todd D.S., Qiao H., Yu M.Y., Busch M.P. A linked donor-recipient study to evaluate parvovirus B19 transmission by blood component transfusion. Blood. 2009. 114 (17). 3677.

FDA Biologics Guidances. www. fda. Gov/Biologics Blood Vaccines/Guidance Compliance Regulatory information/Gui­dances/default.htm (Accessed on March 20, 2017).

Mossong J. et al. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. Epidemiol. Infect. 2008. 136. 1059-1068.

Mortimer P.P., Humphries R.K., Moore J.G., Purcell R.H., YoungN.S. A human parvovirus-like virus inhibits haematopoietic colony formation in vitro. Nature. 1983. 302. 426.

Brown K.E., Anderson S.M., Young N.S. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993. 262. 114.

Lunardi C., Tinazzi E., Bason C., Dolcino M., Corrocher R., Puccetti A. Human parvovirus B19 infection and autoimmunity. Autoimmun. Rev. 2008. 8 (2). 116-20.

Weigel-Kelley K.A., Yoder M.C., Srivastava A. Alpha5beta1 integrin as a cellular coreceptor for human parvovirus B19: requirementof functional activation of beta1 integrin for viral entry. Blood. 2003. 102. 3927.

Munakata Y., Saito-Ito T., Kumura-Ishii K., Huang J., Kodera T., Ishii T., Hirabayashi Y., Koyanagi Y., Sasaki T. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood. 2005. 106. 3449.

Weigel-Van Aken K.A. Pharmacological activation of guanine nucleotide exchange factors for the small GTPase Rap1 recruits high-affinity beta1 integrins as coreceptors for parvovirus B19: improved ex vivo gene transfer to human erythroid progenitor cells. Hum. Gene Ther. 2009. 20 (12). 1665-78.

Seve P. et al. Systemic manifestations of Parvovirus B19 infections. Rev. Med. Interne. 2004 Oct. 25 (10). 740-51.

Heegaard E.D., Brown K.E. Human parvovirus B19. Clin. Microbiol. Rev. 2002. 15 (3). 485-505.

Abe K., Kiuchi T., Tanaca K., Edamoto Y., Ajba N., Sala T. Characterization of erythrovirus B19 genomes isolated in Iiver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transpanlatation. Int. J. Med. Sei. 2007. 4 (2). 105-109.

Левада А.И. Парвовирусная инфекция В19. Педиатр онлайн. 2012.

Ergaz Z., Ornoy A. Parvovirus B19 in pregnancy. Reproductive Toxicology. 2006. 21. 421-435.

Chiasaka H. et al. Parvovirus B19 and the pathogenesis of anaemia. Rev. Med. Virol. 2003 Nov-Dec. 13 (6). 347-59.

Harger J.H., Adler S.P., Koch W.C., and Harger G.F. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet. Gynecol. 1998. 91. 413-420.

Caforio A.L.P., Bottaro S., Iliceto S. Dilated cardiomyopathy (DCM) and myocarditis: classification, clinical and autoimmune features. Applied Cardiopulmonary Pathophysiology. 2012. 16. 82-95.

Norja P. et al. Bioportfolio lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue. Proc. Natl. Acad. Sci. USA. 2006. 103. 7450-7453.

Parvovirus B19 Infection in Pregnancy (2014). Avai­lable from: [ 3161012E.pdf], last accessed Sept 13, 2018.

Neal S. Young, Kevin E. Brown. Parvovirus B19. The New England Journal of Medicine. 2004. 350. 586-97.

de Jong E.P., Walther F.J., Kroes A.C., Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat. Diagn. 2011. 31. 419-425.

Dijkmans A.C., de Jong E.P., Dijkmans B.A., Lopriore E., Vossen A., Walther F.J. et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr. Opin Obstet. Gynecol. 2012. 24. 95-101.

O’Malley A. et al. Parvovirus infects cardiac myocytes in hydrops fetalis. Pediatr. Dev. Pathol. 2003. 6 (5). 414-420.

Lefrère J.J., Servant-Delmas A., Candotti D. et al. Persistent B19 infection in immunocompetent individuals: implications for transfusion safety. Blood. 2005. 106. 2890-2895.

Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of parvovirus B19 infection. J. Intern. Med. 2006. 260. 285-304.

Heegaard E.D., Petersen B.L., Heilmann C.J., Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J. Clin. Microbiol. 2002. 40 (3). 933-6.

Kurtzman G.J., Cohen B.J., Field A.M., Oseas R., Blaese R.M., Young N.S. Immune response to B19 parvovirus infection and an antibody defect in persistent viral infection. J. Clin. Invest. 1989. 84 (4). 1114-23.

Chisaka H., Ito K., Niikura H., Sugawara J., Takano T., Murakami T., Terada Y., Okamura K., Shiroishi H., Sugamura K., Yaegashi N. Clinical manifestations and outcomes of parvovirus B19 infection duting pregnancy in Tohoku. J. Exp. Med. 2006. 209. 277-283.

Corcioli F., Zakrzewska K., Fanci R., De Giorgi V., Innocenti M., Rotellini M., Di Lollo S., Azzi A. Human parvovirus PARV4 DNA in tissues from adult individuals: a comparison with human parvovirus B19 (B19V). Virol. J. 2010. 7. 272. Mode of access. 568-1.

Young N.S., Brown K.E. Mechanisms of disease: Parvovirus. N. Engl. J. Med. 2004. 350 (6). 586-597.

Noyola D.E., Lourdes Padilla-Ruiz M., Guadalupe Obregón-Ramos M. et al. Parvovirus B19 infection in medical students during a hospital outbreak. J. Med. Microbiol. 2004. 53. 141-146.

Tolfvenstam T., Broliden K. Parvovirus B19 infection. Semin. Fetal. Neonatal. Med. 2009. 14 (4). 218-221.

Anderson L.J. Role of parvovirus B19 in human disease. Pediatr. Infect. Dis. 1987. 6. 711-718.

Koch W.C. Fifth (human parvovirus) and sixth (herpesvirus 6) diseases. Curr. Opin. Infect. Dis. 2001. 14. 343-356.

Nicolay N. et al. Clinical and epidemiological aspects of parvovirus B19 infections in Ireland, January 1996-June 2008. Euro Surveill. 2009. 14. 1-5.

Valentin M.N., Cohen P.J. Pediatric Parvovirus B19: spectrum of clinical manifestations. Cutis. 2013. 92. 179-184.

Pavlovic M.D. Papular-purpuric «gloves and socks» syndrome caused by parvovirus B19. Vojnosanit Pregl. 2003. 60 (2). 223-225.

Heckler G.T., Dal Ri N.M.K., Almeida H.L. Jr. Case for diagnosis. An. Bras. Dermatol. 2012. 87 (5). 793-794.

Kumano K. Various clinical symptoms in human parvovirus B19 infection. Japanese Journal of Clinical Immunology. 2008. 31 (6). 448-453.

Muir K., Todd W.T., Watson W.H., Fitzsimons E. Viral-associated haemophagocytosis with parvovirus-B19-related pancytopenia. Lancet. 1992. 339. 1139-1140.

Poole B.D., Karetnyi Y.V., Naides S.J. Parvovirus B19-induced apoptosis of hepatocytes. Journal of virology. 2004. 78 (14). 7775-7783.

Bihari Ch., Rastogi A., Saxena P. et al. Parvovirus B19 associated hepatitis. Hindawi Publishing Corporation. Hepatitis Research and Treatment. 2013. Article ID 472027. 1-9.

Mihály I., Trethon A., Arányi Z. et al. Observations on human parvovirus B19 infection diagnosed in 2011. Orvosi Hetilap. 2012. 153 (49). 1948-1957. View at Google Scholar.

Sun L., Zhang J.-C. Acute fulminant hepatitis with bone marrow failure in an adult due to parvovirus B19 infection. Hepatology. 2012. 55 (1). 329-330.

Yang S.-H., Lin L.-W., Fang Y.-J., Cheng A.-L., Kuo S.-H. Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. Annals of Hematology. 2012. 91 (2). 291-294.

Hatakka A., Klein J., He R. et al. Acute hepatitis as a manifestation of parvovirus B19 infection. Journal of Clinical Microbiology. 2011. 49 (9). 3422-3424.

Kindermann I., Barth C., Mahfoud F. et al. Update on Myocarditis. Journal of the American College of Cardiology. 2012. 59 (9). 779-792.

Schultheiss H.-P., Kuhl U., Cooper L.T. The management of myocarditis. European Heart Journal. 2011; doi:10.1093. 1-13.

Lotze U., Egerer R., Gluck B., Zell R., Sigusch H., Erhardt C., Heim A., Kandolf R., Bock T., Wutzler P., Figulla H.R. Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J. Med. Virol. 2010. 82. 1449-1457.

Schenk T., Enders M., Pollak S., Hahn R., Huzly D. High prevalence of human parvovirus B19 DNA in myocardial autopsy samples from subjects without myocarditis or dilative cardiomyopathy. J. Clin. Microbiol. 2009. 47. 106-110.

Barah F., Whiteside S. et al. Neurological aspects of human parvovirus B19 infection: a systematic review. J. Rev. Med. Virol. 2014 May. 24 (3). 154-68.

Douvoyiannis M., Litman N., Goldman D.L. Neurologic manifestations associated with Parvovirus B19 Infection. CID. 2009. 48 (15). 1713-1723.

Alger L.S. Toxoplasmosis and parvovirus B19. Infect. Dis. Clin. North Am. 1997. 11. 55-75.

Waring G.J. Parvovirus B19 infection. Timely diagnosis in pregnancy essential. Case Rep. Womens Health. 2018. 18. e00057. DOI. 10.1016/j.crwh.2018. e00057

Ornoy A., Ergaz Z. Parvovirus. B19 infection during pregnancy and risks to the fetus. Birth. Defects Res. 2017. Mar 15. 109 (5). 311-323.

Courtier J., Schauer G.M., Parer J.T., Regenstein A.C., Callen P.W., Glenn O.A. Parvovirus. B19 infection during pregnancy and risks to the fetus. Ultrasound Obstet Gynecol. 2012. 40 (5). 604-6.

Röhrer C.I., Gärtner B., Sauerbrei A., Böhm, S., Hottenträger B., Raab U. et al. Seroprevalence of parvovirus B19 in the German population. Epidemiol. Infect. 2008. 136. 1564-1575.

Valeur-Jensen A.K., Pedersen C.B., Westergaard T., Jensen I.P., Lebech M., Andersen P.K. et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999. 281. 1099-1105.

Centers for Disease Control (CDC). Risks associated with human parvovirus B19 infection. Morb. Mortal. Wkly. Rep. 1989. 38. 81-88 (93-7).

Gilbert N.L. et al. Seroprevalence of parvovirus B19 infection in daycare educators. Epidemiol. Infect. 2005. 133. 299-304.

Giorgio E., Antonietta De Oronzo M., Iozza I. Parvovirus B19 during pregnancy: a review. Journal of Prenatal Medicine. 2010. 4 (4). 63-66.

Schulert G.S., Walsh W.F., Weitkamp J.H. Polymicrogyria and congenital Parvovirus B19 infection. Am. J. Perinatol. Rep. 2011. 1. 105-110.

Crane J., Mundle W., Boucoiran I. Parvovirus B19 infection in pregnancy. 2014 Dec. 36 (12). 1107-1116.

Leduc L. SOGC Maternal-Fetal Medicine Committee. Stillbirth and bereavement: guidelines for stillbirth investigation. SOGC Clinical Practice Guidelines. J. Obstet. Gynaecol. Can. 2006. 28. 540-552.

Watt A.P., Brown M., Pathiraja M., Anbazhagan A., Coyle P.V. The lack of routine surveillance of parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by occupational exposure. J. Med. Microbiol. 2013. 62. 86-92.

Simms R.A., Liebling R.E., Patel R.R., Denbow M.L., Abdel-Fattah S.A., Soothill P.W. et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal. Diagn. Ther. 2009. 25. 373-378.

Enders M., Schalasta G., Baisch C., Weidner A., Pukkila L., Kaikkonen L. et al. Human parvovirus B19 infection during pregnancy-value of modern molecular and serological diagnostics. J. Clin. Virol. 2006. 35. 400-406.

Australasian Society for Infectious Diseases. Management of Perinatal Infection (2014). Available from: [], last accessed Sept 13, 2018.

SOGC Clinical Practice guideline. Parvovirus B19 Infection in Pregnancy (2014). Available from: [], last accessed Sept 13, 2018.

Enders M., Weidner A., Zoellner I., Searle K., Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat. Diagn. 2004. 24. 513-518.

Matsuda H., Sakaguchi K., Shibasaki T., Takahashi H. et al. Intrauterine therapy for parvovirus B19 infected sympto­matic fetus using B19 IgG-rich high titer gammaglobulin. J. Perinat. Med. 2005. 33 (6). 561-563.

Sarfraz A.A., Samuelsen S.O., Bruu A.L., Jenum P.A., Eskild A. Maternal human parvovirus B19 infection and the risk of fetal death and low birthweight: a case-control study within 35 940 pregnant women. BJOG. 2009. 116. 1492-8.

Smith J. Human parvovirus B19: a literature review and case study. Infant. 2008. 4 (5). 101-104.

de Haan T.R., van den Akker E.S., Porcelijn L., Oepkes D., Kroes A.C., Walther F.J. Thrombocytopenia in hyd­ropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load: BJOG. 2008. 115. 76-81.

Adler S. and Koch W.C. Human parvovirus B19. In: J.S. Remington, J.O. Klein (Eds.) Infectious diseases of the fetus and newborn infant. 7th ed. Saunders, Philadelphia. 2010. 845 (5).

Cohen B. Parvovirus B19: an expanding spectrum of di­sease. BMJ. 1995. 311. 1549-1552.

Levy R., Weissman A., Blomberg G., Hagay Z.J. Infection by parvovirus B19 during pregnancy: a review. Obstet. Gynecol. Surv. 1997. 52. 254-259.

Segata M., Chaoui R., Khalek N., Bahado-Singh R., Paidas M.J., Mari G. Fetal thrombocytopenia secondary to parvovirus infection. Am. J. Obstet. Gynecol. 2007. Jan. 196 (1). 61. e1-4.

Enders M., Weidner A., Zoellner I., Searle K., Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat. Diagn. 2004 Jul. 24 (7). 513-8.

Markenson G.R., Yancey M.K. Parvovirus B19 infections in pregnancy. Semin. Perinatol. 1998. 22. 309-317.

Barton L.L., Lax D., Shehab Z.M., Keith J.C. Congenital cardiomyopathy associated with human parvovirus B19 infection. Am. Heart J. 1997. 133. 131-133.

Enders M., Weidner A., Rosenthal T., Baisch C., Hedman L., Söderlund-Venermo M., Hedman K. Improved diagnosis of gestational parvovirus B19 infection at the time of nonimmune fetal hydrops. J. Infect. Dis. 2008. 197. 58-62.

Health Protection Agency Rash Guidance Working Group. Guidance on viral rash in pregnancy: investigation, diagnosis and management of viral rash illness, or exposure to viral rash illness, in pregnancy. Health Protection Agency, London. 2011.

Miller E., Fairley C.K., Cohen B.J., Seng C. Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br. J. Obstet. Gynaecol. 1998. 105. 174-178.

Nyman M., Tolfvenstam T., Petersson K., Krassny C., Skjöldebrand-Sparre L., Broliden K. Detection of Human Parvovirus B19 Infection in First-Trimester Fetal Loss. Obstetrics & Gynecology. 2002. 99 (5). Part 1. 795-798.

von Kaisenberg C.S., Jonat W. Fetal parvovirus B19 infection. Ultrasound. Obstet. Gynecol. 2001. 18. 280-288.

Rodis J.F. Parvovirus infection. Clin. Obstet. Gynecol. 1999. 42. 107-120 (quiz 174-5).

Barrett J., Ryan G., Morrow R., Farine D., Kelly E., Mahony J. Human parvovirus B19 during pregnancy. J. Soc. Obstet. Gynaecol. Can. 1994. 16. 1253-1258.

Borna S., Mirzaie F., Hanthoush-Zadeh S., Khazar­doost S., Rahimi-Sharbaf F. Middle cerebral artery peak systolic velocity and ductus venosus velocity in the investigation of nonimmune hydrops. J. Clin. Ultrasound. 2009. 37. 385-388.

Chauvet A., Dewilde A., Thomas D., Joriot S., Vaast P., Houfflin-Debarge V. et al. Ultrasound diagnosis, management and prognosis in a consecutive series of 27 cases of fetal hydrops following maternal parvovirus B19 infection. Fetal. Diagn. Ther. 2011. 30. 41-47.

Delle Chiaie L., Buck G., Grab D., Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001. 18. 232-236.

Morgan-Capner P. Guidelines on the management of, and exposure to, rash illness in pregnancy (including consideration of relevant antibody screening programmes in pregnancy). Commun. Dis. Public Health. 2002. 5. 59-71.

Koppelman M.H.G.M. et al. Quantitative real-time detection of parvovirus B19 DNA in plasma. Transfusion. 2004. 44. 97-103.

Rodis J.F., Hovick T.J. Jr., Quinn D.L., Rosengren S.S., Tattersall P. Human parvovirus infection in pregnancy. Obstet. Gynecol. 1988. 72. 733-738.

Bernstein D.I., Sahly H., Keitel W.A. et al. Safety and immunogenicity of a candidate Parvovirus B19 vaccine. Vaccine. 2011. 29 (43). 7357-7363.

Pickering L.K., Baker C.J., Kimberlin D.W. et al. Parvovirus B19. Report of the Committee on Infectious Diseases. American Academy of Pediatrics. 2009. 491-494.

Copyright (c) 2019 ACTUAL INFECTOLOGY

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта